^
Association details:
| Biomarker: | KMT2A rearrangement |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | Blincyto (blinatumomab) (CD3 agonist, CD19 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
826 Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial
Published date:
11/02/2023
Excerpt:
All patients with KMT2A and TCF3::PBX1 rearrangements achieved a CR...This phase II trial shows the benefit of adding blinatumomab for the management of Ph- B-ALL, with the primary objective being achieved with 93% of patients being MRDneg after the 1st cycle of blinatumomab. With a median follow-up of 37.5 months, OS and DFS are 71% and 66%, respectively, better than in historical results, particularly in patients up to the age of 55.
Secondary therapy:
Chemotherapy
